1. A pharmaceutical composition comprising: a) a therapeutic chemical compound having anti-inflammatory activity, wherein the therapeutic chemical compound has a log P value of greater than 2.0； b) a pharmaceutically acceptable solvent, wherein the solvent comprises a pharmaceutically acceptable polymer polyethylene glycol and a pharmaceutically acceptable alcohol or a pharmaceutically acceptable ester of a pharmaceutically acceptable alcohol and acid； and c) a pharmaceutically acceptable adjuvant, wherein the adjuvant is at least 80 vol% of the pharmaceutical composition. The pharmaceutical composition according to claim 1, wherein the anti-inflammatory activity decreases the level of the inflammation-inducing molecule, decreases the level of inflammation-inducing prostaglandin, stimulates the PPAR signaling pathway, induces apoptosis of M1 macrophage cells, stimulates the differentiation of M2 macrophage cells, and has both of these effects, lowers gamma interferon levels ( IFNγ), tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), or a combination thereof, released from Th1 cells, increases the level of IL-10 released from Th2 cells, or o shows both of these actions. 3. The pharmaceutical composition according to claim 1, wherein the therapeutic chemical compound is a non-steroidal anti-inflammatory drug (NSAID), a PPARγ agonist, fibrate and / or ester thereof. The pharmaceutical composition according to claim 3, wherein the NSAID is an NSAID derivative of a salicylate, an NSAID derivative of p-aminophenol, an NSAID derivative of propionic acid, an NSAID derivative of acetic acid, an NSAID derivative of enolic acid, an NSAID derivative of fenamic acid1. Фармацевтическая композиция, содержащая:a) терапевтическое химическое соединение, обладающее противовоспалительной активностью, где данное терапевтическое химическое соединение имеет значение log P более чем 2,0；b) фармацевтически приемлемый растворитель, где данный растворитель включает фармацевтически п
